Parasites, Hosts and Diseases

  • 제59권3호
  • /
  • Pages.189-225
  • /
  • 2021
  • /
  • 2982-5164(pISSN)
  • /
  • 1738-0006(eISSN)
대한기생충학·열대의학회 (The Korea Society for Parasitology and Tropical Medicine)
권호 표지
DOI QR코드

DOI QR Code

Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update

  • Chai, Jong-Yil (Institute of Parasitic Diseases, Korea Association of Health Promotion) ;
  • Jung, Bong-Kwang (Institute of Parasitic Diseases, Korea Association of Health Promotion) ;
  • Hong, Sung-Jong (Department of Environmental Medical Biology, Chung-Ang University College of Medicine)
  • 투고 : 2021.05.03
  • 심사 : 2021.05.27
  • 발행 : 2021.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The use of albendazole and mebendazole, i.e., benzimidazole broad-spectrum anthelmintics, in treatment of parasitic infections, as well as cancers, is briefly reviewed. These drugs are known to block the microtubule systems of parasites and mammalian cells leading to inhibition of glucose uptake and transport and finally cell death. Eventually they exhibit ovicidal, larvicidal, and vermicidal effects on parasites, and tumoricidal effects on hosts. Albendazole and mebendazole are most frequently prescribed for treatment of intestinal nematode infections (ascariasis, hookworm infections, trichuriasis, strongyloidiasis, and enterobiasis) and can also be used for intestinal tapeworm infections (taeniases and hymenolepiasis). However, these drugs also exhibit considerable therapeutic effects against tissue nematode/cestode infections (visceral, ocular, neural, and cutaneous larva migrans, anisakiasis, trichinosis, hepatic and intestinal capillariasis, angiostrongyliasis, gnathostomiasis, gongylonemiasis, thelaziasis, dracunculiasis, cerebral and subcutaneous cysticercosis, and echinococcosis). Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine. Albendazole was tried even for treatment of trematode (fascioliasis, clonorchiasis, opisthorchiasis, and intestinal fluke infections) and protozoan infections (giardiasis, vaginal trichomoniasis, cryptosporidiosis, and microsporidiosis). These drugs are generally safe with few side effects; however, when they are used for prolonged time (>14-28 days) or even only 1 time, liver toxicity and other side reactions may occur. In hookworms, Trichuris trichiura, possibly Ascaris lumbricoides, Wuchereria bancrofti, and Giardia sp., there are emerging issues of drug resistance. It is of particular note that albendazole and mebendazole have been repositioned as promising anti-cancer drugs. These drugs have been shown to be active in vitro and in vivo (animals) against liver, lung, ovary, prostate, colorectal, breast, head and neck cancers, and melanoma. Two clinical reports for albendazole and 2 case reports for mebendazole have revealed promising effects of these drugs in human patients having variable types of cancers. However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popularly used than albendazole in anti-cancer clinical trials.

키워드

과제정보

We are grateful to the staff of Institute of Parasitic Diseases, Korea Association of Health Promotion, Seoul, Korea who helped this study. We dedicate this review article to late Prof. Emer. HanJong Rim, Korea University, Seoul, Korea, a pioneer of anthelmintics and parasitology research, who recently passed away.

참고문헌

  1. Theodorides VJ, Gyurik RJ, Kingsbury WD, Parish RC. Anthelmintic activity of albendazole against liver flukes, tapeworms, lung and intestinal roundworms. Experientia 1976; 32: 702-703. https://doi.org/10.1007/BF01919842
  2. Pene P, Mojon M, Garin JP, Coulaud JP, Rossignol JF. Albendazole: a new broad spectrum anthelmintic. Double-blind multi-center clinical trial. Am J Trop Med Hyg 1982; 31: 263-266. https://doi.org/10.4269/ajtmh.1982.31.263
  3. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 2003; 86: 141-159. https://doi.org/10.1016/S0001-706X(03)00031-7
  4. Brugmans JP, Theinpont DC, Wijngaarden IV, Vanparijs OF, Schuermans VL, Lauwers HL. Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects. JAMA 1971; 217: 313-316. https://doi.org/10.1001/jama.1971.03190030039008
  5. Pawluk SA, Roels CA, Wilby KJ, Ensom MHH. A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole. Clin Pharmacokinet 2015; 54: 371-383. https://doi.org/10.1007/s40262-015-0243-9
  6. Edwards G, Brechenridge AM. Clinical pharmacokinetics of anthelmintic drugs. Clin Pharmacokinet 1988; 15: 67-93. https://doi.org/10.2165/00003088-198815020-00001
  7. Kern P. Echinococcus granulosus infection: clinical presentation, medical treatment and outcome. Langenbecks Arch Surg 2003; 388: 413-420. https://doi.org/10.1007/s00423-003-0418-y
  8. Chai JY, Hong ST. Chemotherapy of intestinal nematode infections. J Korean Soc Chemother 1985; 3: 119-129.
  9. Chai JY. Recent advances in the use of anthelmintics for treating nematode infections. Infect Chemother 2011; 43: 26-35 (in Korean). https://doi.org/10.3947/ic.2011.43.1.26
  10. Keiser J, Utzinger J. The drugs we have and the drugs we need against major helminth infections. Adv Parasitol 2010; 73: 197-230. https://doi.org/10.1016/S0065-308X(10)73008-6
  11. Hong ST. Albendazole and praziquantel: review and safety monitoring in Korea. Infect Chemother 2018; 50: 1-10. https://doi.org/10.3947/ic.2018.50.1.1
  12. Jamet D, Quinio D, Moalic E, Ianotto JC, Dalbies F, Guillerm G, Marion V, Berthou C, Nevez G. Systemic microsporidiosis and toxoplasmosis in a patient with T lymphocytic leukemia. Med Mal Infect 2009; 39: 406-408 (in French). https://doi.org/10.1016/j.medmal.2008.10.018
  13. Rim HJ, Joo KH, Lee JS, Wang JS. Anthelmintic effects of albendazole (Zentel®) against helminthic infections. Korean J Rural Med 1984; 9: 67-73 (in Korean). https://www.koreascience.or.kr/article/JAKO198431462787922.page
  14. Pungpark S, Bunnag D, Harinasuta T. Albendazole in the treatment of opisthorchiasis and concomitant intestinal helminthic infections. Southeast Asian J Trop Med Public Health 1984; 15: 44-50.
  15. Keiser J, Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin Pharmacother 2004; 5: 1711-1726. https://doi.org/10.1517/14656566.5.8.1711
  16. Fan PC, Wu CC, Huang P, Yen CW. Determination of the minimum effective dosages of praziquantel, albendazole, and mebendazole against Clonorchis sinensis infection in rats. Kaohsiung J Med Sci 2005; 21: 448-451. https://doi.org/10.1016/S1607-551X(09)70149-4
  17. Khan W, Iqbal M, Dad O. Have we forgotten the threat posed by fascioliasis? A potential threat to public health. Iran J Public Health 2020; 49: 814-815.
  18. Xu LL, Jiang B, Duan JH, Zhuang SF, Liu YC, Zhu SQ, Zhang LP, Zhang HB, Xiao SH, Zhou XN. Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths. PLoS Negl Trop Dis 2014; 8: e3046. https://doi.org/10.1371/journal.pntd.0003046
  19. Jaroonvesama N, Charoenlarp K, Cross JH. Treatment of Opisthorchis viverrini with mebendazole. Southeast Asian J Trop Med Public Health 1981; 12: 595-597.
  20. Dugernier T, Geubel A, Bigaignon G, Cesbron JY, Coche E. Human fascioliasis: cure by mebendazole? A case report. Gastroenterol Clin Biol 1986; 10: 513-516.
  21. Rim HJ, Joo KH, Park HS. Anthelmintic effects of albendazole against Taenia saginata and Taenia solium infections. J Korean Soc Chemother 1989; 7: 29-39.
  22. Takayanagui OM, Odashima NS, Bonato PS, Lima JE, Lanchote VL. Medical management of neurocysticercosis. Expert Opin Pharmacother 2011; 12: 2845-2856. https://doi.org/10.1517/14656566.2011.634801
  23. Steinmann P, Utzinger J, Du ZW, Jiang JY, Chen JX, Hattendorf J, Zhou H, Zhou XN. Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a randomized controlled trial. PLoS One 2011; 6: e25003. https://doi.org/10.1371/journal.pone.0025003
  24. Tamarozzi F, Nicoletti GJ, Neumayr A, Brunetti E. Acceptance of standardized ultrasound classification, use of albendazole, and long-term follow-up in clinical management of cystic echinococcosis: a systematic review. Curr Opin Infect Dis 2014; 27: 425-431. https://doi.org/10.1097/QCO.0000000000000093
  25. Qavi A, Garg RK, Malhotra HS, Jain A, Kumar N, Malhotra KP, Srivastava PK, Verma R, Sharma PK. Disseminated cysticercosis: clinical spectrum, Toll-like receptor-4 gene polymorphisms and role of albendazole. Medicine 2016; 95: e4882. https://doi.org/10.1097/MD.0000000000004882
  26. Molina JM, Oksenhendler E, Beauvais B, Sarfati C, Jaccard A, Derouin F, Modai J. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171: 245-249. https://doi.org/10.1093/infdis/171.1.245
  27. Sak B, Brdickova K, Holubova N, Kvetonova D, Hlaskova L, Kvac M. Encephalitozoon cuniculi genotype III evinces a resistance to albendazole treatment in both immunodeficient and immunocompetent mice. Antimicrob Agents Chemother 2020; 64: e00058-20. https://doi.org/10.1128/AAC.00058-20
  28. Darlan DM, Hartanto SJ, Rozi MF. The comparison of efficacy and side effect between albendazole and metronidazole in the management of giardiasis: a systematic review and meta-analysis. EuroMeditter Biomed J 2020; 15: 191-196. https://doi.org/10.3269/1970-5492.2020.15.45
  29. Palos I, Moo-Puc R, Vique-Sanchez JL, Benitez-Cardoza CG, Monge A, Villalobos-Rocha JC, Paz-Gonzalez AD, Rivera G. Esters of quinolone-7-carboxylate-1,4-di-N-oxide as Trichomonas vaginalis triosephosphate isomerase inhibitors. Acta Pharm 2021; 71: 485-495. https://doi.org/10.2478/acph.2021-0032
  30. Sears SD, O'hare J. In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrobial Agents Chemother 1988; 32: 144-146. https://doi.org/10.1128/AAC.32.1.144
  31. Cedillo-Rivera R, Munoz O. In-vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents. J Med Microbiol 1992; 37: 221-224. https://doi.org/10.1099/00222615-37-3-221
  32. Patziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience 2014; 8: 443. https://doi.org/10.3332/ecancer.2014.44332.
  33. Castro LSEPW, Kviecinski MR, Ourique F, Parisotto EB, Grinevicius VMAS, Correia JFG, Filho DW, Pedrosa RC. Albendazole as a promising molecule for tumor control. Radix Biol 2016; 10: 90-99. https://doi.org/10.1016/j.redox.2016.09.013
  34. Guerini AE, Triggiani L, Maddalo M, Bonu ML, Frassine F, Baiguini A, Alghisi A, Tomasini D, Borghetti P, Pasinetti N, Bresciani R, Magrini SM, Buglione M. Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers 2019; 11: 1284. https://doi.org/10.3390/cancers11091284
  35. Son DS, Lee ES, Adunyah SE. The antitumor potentials of benzimidazole anthelmintics as repurposing drugs. Immun Netw 2020; 20: e29. https://doi.org/10.4110/in.2020.20.e29
  36. Braithwaite PA, Thomas RJS, Thompson RCA. Hydatid disease: the alveolar variety in Australia. A case report with comment on the toxicity of mebendazole. Aust N Z J Surg 1985; 55: 519-523. https://doi.org/10.1111/j.1445-2197.1985.tb00935.x
  37. Morris DL, Jourdan JL, Pougholami MH. Pilot study of albendazole in patients with advanced malignancy. Oncology 2001; 61: 42-46. https://doi.org/10.1159/000055351
  38. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001; 165: 43-49. https://doi.org/10.1016/S0304-3835(01)00382-2
  39. Moon SY, Baek YH, Lee SW. Drug induced liver injury by prophylactic administration of albendazole. Korean J Gastroenterol 2019; 73: 360-364 (in Korean). https://doi.org/10.4166/kjg.2019.73.6.360
  40. Krucken J, Fraundorfer K, Mugisha JC, Ramunke S, Sifft KC, Geus D, Habarugira F, Ndoli J, Sendegeya A, Mukampunga C, Bayingana C, Aebischer T, Demeler J, Gahutu JB, Mockenhaupt FP, von Samson-Himmelstjerna G. Reduced efficacy of albendazole against Ascaris lumbricoides in Rwandan schoolchildren. Int J Parasitol Drugs Drug Resist 2017; 7: 262-271. https://doi.org/10.1016/j.ijpddr.2017.06.001
  41. Rashwan N, Bourguinat C, Keller K, Gunawardena NK, de Silva N, Prichard R. Isothermal diagnostic assays for monitoring single nucleotide polymorphisms in Necator americanus associated with benzimidazole drug resistance. PLoS Negl Trop Dis 2016; 10: e0005113. https://doi.org/10.1371/journal.pntd.0005113
  42. Moser W, Schindler C, Keiser J. Drug combinations against soil-transmitted helminth infections. Adv Parasitol 2019; 103: 91-115. https://doi.org/10.1016/bs.apar.2018.08.002
  43. Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ 2017; 358: j4307. https://doi.org/10.1136/bmj.j4307
  44. Soukhathammavong PA, Sayasone S, Phongluxa K, Xayaseng V, Utzinger J, Vounatsou P, Hatz C, Akkhavong K, Keiser J, Odermatt P. Low efficacy of single-dose albendazole and mebendazole against hookworm and effect on concomitant helminth infection in Lao PDR. PLoS Negl Trop Dis 2012; 6: e1417. https://doi.org/10.1371/journal.pntd.0001417
  45. World Health Organization. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases. 2nd ed. World Health Organization. Geneva, Switzerland. 1995, pp 1-146.
  46. Chai JY, Sohn WM, Hong SJ, Jung BK, Hong S, Cho S, Park JB, Kim IS, Kim S, Lee KH, Jeoung HG, Htoon TT, Tin HH. Effect of mass drug administration with a single dose of albendazole on Ascaris lumbricoides and Trichuris trichiura infection among schoolchildren in Yangon Region, Myanmar. Korean J Parasitol 2020; 58: 195-200. https://doi.org/10.3347/kjp.2020.58.2.195
  47. Chaia G, Sales da Cunha A. Therapeutic action of mebendazole (R 17,635) against human helminthiasis. Folha Med 1971; 63: 843-852.
  48. Chavarria AP, Swartzwelder JC, Villarejos VM, Zeledon R. Mebendazole, an effective broad-spectrum anthelmintic. Am J Trop Med Hyg 1973; 22: 592-595. https://doi.org/10.4269/ajtmh.1973.22.592
  49. Seo BS, Cho SY, Chai JY. Reduced single dose of mebendazole in treatment of Ascaris lumbricoides infection. Korean J Parasitol 1978; 16: 21-25. http://dx.doi.org/10.3347/kjp.1978.16.1.21
  50. Abadi K. Single dose mebendazole therapy for soil-transmitted nematodes. Am J Trop Med Hyg 1985; 34: 129-133. https://doi.org/10.4269/ajtmh.1985.34.129
  51. Pene P, Coulaud JP, Soula G, Rossignol JF, Monges P, Chaudet H. Le Zentel® dans traitement des helminthiases intestinales en Afrique de l'Ouest. Med Afr Noire 1982; 29: 43-48 (in French).
  52. Soula G, Stopathis RM. Le Zentel® dans le traitement des nematodoses intestinales en Republique Centrafricaine. Med Afr Noire 1982; 29: 29-32 (in French).
  53. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 2000; 121 (suppl): 113-132. https://doi.org/10.1017/s0031182000007290
  54. Seo BS, Cho SY, Kang SY, Chai JY. Anthelmintic efficacy of methyl-5-benzoylbenzimidazle-2-carbamate (mebendazole) against multiple helminthic infections. Korean J Parasitol 1977; 15: 11-16. http://dx.doi.org/10.3347/kjp.1977.15.1.11
  55. Sinniah B, Sinniah D, Dissanaike AS. Treatment of intestinal nematodes with single dose treatment of oxantel-pyrantel pamoate plus mebendazole. In Asian Parasite Control Organization Research Group ed, Collected Papers on the Control of Soil-Transmitted Helminthiases by Asian Parasite Control Organization (APCO). Tokyo, Japan. The Asian Parasite Control Organization 1980, pp 321-325.
  56. Coulaud JP, Duchatelle C, Rouvillois A, Deluol AM. Le Zentel® dans le traitement des helminthiases intestinales, au Niger, en Guinee et a Paris. Med Afr Noire 1982; 29: 41-42 (in French).
  57. Kim CH. Clinical trials of mebendazole (Vermox) on Ascaris and Trichuris infection. Chungnam Med J 1975; 2: 207-211 (in Korean).
  58. Seo BS, Lee SH, Chai JY, Hong ST, Hong SJ. Efficacy of mebendazole in treatment and control of trichuriasis in Korea. Korean J Parasitol 1983; 21: 95-101. http://dx.doi.org/10.3347/kjp.1983.21.1.95
  59. Henriquez-Camacho C, Gottuzzo E, Echevarria J, White AC Jr, Terashima A, Samalvides F, Perez-Molina JA, Plana MN. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Datab Syst Rev 2016; 2016: CD007745. http://doi.org/10.1002/14651858.CD007745.pub3
  60. Hong SJ, Han JH. A case of Strongyloides stercoralis infection. Korean J Parasitol 1999; 37: 117-120. https://doi.org/10.3347/kjp.1999.37.2.117
  61. Echazu A, Juarez M, Vargas PA, Cajal SP, Cimino RO, Heredia V, Caropresi S, Paredes G, Arias LM, Abril M, Gold S, Lammie P, Krolewiecki AJ. Albendazole and ivermectin for control of soil-transmitted helminths in an area with high prevalence of Strongyloides stercoralis and hookworm in northwestern Argentina: a community-based pragmatic study. PLoS Negl Trop Dis 2017; 11: e0006003. http://doi.org/10.1371/journal.pntd.0006003
  62. Chai JY, Hong ST, Sohn WM, Lee SH. Anthelmintic effect of albendazole (Alzental@) on human intestinal nematodes. J Korean Soc Chemother 1986; 4: 86-88 (in Korean).
  63. St Georgiev V. Chemotherapy of enterobiasis (oxyuriasis). Expert Opin Pharmacother 2001; 2: 267-275. https://doi.org/10.1517/14656566.2.2.267
  64. Cho SY, Ahn YR, Ryang YS, Seo BS. Evaluation of anthelmintic treatment on Enterobius vermicularis infection in highly endemic population by prolonged observation. Korean J Parasitol 1977; 15: 100-108. http://dx.doi.org/10.3347/kjp.1977.15.2.100
  65. Hong ST, Chai JY, Cho SY, Seo BS, Yun CK. Efficacy of repeated chemotherapy in control of Enterobius vermicularis infection. Seoul J Med 1979; 20: 163-168. https://snucm.elsevierpure.com/en/publications/efficacy-of-repeated-chemotherapy-in-control-of-enterobius-vermic
  66. Steinmann P, Zhou XN, Du ZW, Jiang JY, Xiao SH, Wu ZX, Zhou H, Utzinger J. Tribendimidine and albendazole for treating soil-transmitted helminths, Strongyloides stercoralis and Taenia spp.: open-label randomized trial. PLoS Negl Trop Dis 2008; 2: e322. https://doi.org/10.1371/journal.pntd.0000322
  67. Soh CT, Lee BH, Min DY, Chang SJ, Lee JH. Clinical trial of Vermox (mebendazole), a new broadspectrum anthelmintic. Yonsei Rep Trop Med 1974; 5: 148-152.
  68. Chavarria AP, Villarejos VM, Zeledon R. Mebendazole in the treatment of taeniasis solium and taeniasis saginata. Am J Trop Med Hyg 1977; 26: 118-120. https://doi.org/10.4269/ajtmh.1977.26.118
  69. Chai JY. Praziquantel treatment in trematode and cestode infections: an update. Infect Chemother 45: 32-43. https://doi.org/10.3947/ic.2013.45.1.32
  70. Rossignol JF, Maisonneuve H. Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis. Trans R Soc Trop Med Hyg 1983; 77: 707-711. https://doi.org/10.1016/0035-9203(83)90211-0
  71. Keystone JS, Murdocch JK. Mebendazole. Ann Intern Med 1979; 91: 582-586. https://doi.org/10.7326/0003-4819-91-4-582
  72. Kong L, Peng HJ. Current epidemic situation of human toxocariasis in China. Adv Parasitol 2020; 109: 433-448. https://doi.org/10.1016/bs.apar.2020.01.016
  73. Nicholas WL, Stewart AC. The action of benzimidazoles on the larval stage of Toxocara canis in the mouse. Ann Trop Med Parasitol 1979; 73: 57-62. https://doi.org/10.1080/00034983.1979.11687227
  74. Sturchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol 1989; 83: 473-478. https://doi.org/10.1080/00034983.1989.11812374
  75. Barisani-Asenbauer T, Maca SM, Hauff W, Kaminski SL, Domanovits H, Theyer I, Auer H. Treatment of ocular toxocariasis with albendazole. J Ocul Pharmacol Therapeut 2001; 17: 287-294. https://doi.org/10.1089/108076801750295317
  76. Anonymous. Drugs for parasitic infections. Med Lett Drugs Ther 2004; 1189: 1-12.
  77. Singer OC, Conrad F, Jahnke K, Hattingen E, Auer H, Steinmetz H. Severe meningoencephalomyelitis due to CNS-toxocarosis. J Neurol 2011; 258: 696-698. https://doi.org/10.1007/s00415-010-5807-x
  78. Feske SK, Goldberg M, Dudzinski DM, Gonzalez RG, Kovach AE. Case 29-2015: a 38-year-old pregnant woman with headache and visual symptoms. N Engl J Med 2015; 373: 1154-1164. https://doi.org/10.1056/NEJMcpc1404335
  79. Melliou M, Mavridis IN, Pyrgelis ES, Agapiou E. Toxocariasis of the nervous system. Acta Parasitol 2020; 65: 291-299. https://doi.org/10.2478/s11686-019-00166-1
  80. Hombu A, Yoshida A, Kikuchi T, Nagayasu E, Kuroki M, Maruyama H. Treatment of larva migrans syndrome with long-term administration of albendazole. J Microbiol Immunol Infect 2019; 52: 100-105. https://doi.org/10.1016/j.jmii.2017.07.002
  81. Magnaval JF. Comparative efficacy of diethylcarbamazine and mebendazole for treatment of human toxocariasis. Parasitology 1995; 110: 529-533. https://doi.org/10.1017/S0031182000065240
  82. Coulaud JP, Binet D, Voyer C, Samson C, Moreau G, Rossignol JF. Treatment of cutaneous larva migrans "Larbish' with albendazole: report of 18 cases. Bull Soc Pathol Exot Filiales. 1982; 75: 534-537 (in French).
  83. Thadchanamoorthy V, Dayasiri K. Cutaneous larvae migrans infestation over buttocks and perianal region: a case series of five toddlers from Sri Lanka and literature review. Cureus 2020; 12: e11335. https://doi.org/10.7759/cureus.11335
  84. Mulia RC, Djawad K, Adriani A, Idrus I. Office-made 4% albendazole cream is an effective alternative therapy for cutaneous larva migrans: a report of three cases. Serbian J Dermatol Venerol 2020; 12: 9-13. https://doi.org/10.2478/sjdv-2020-0002
  85. Tan SK, Liu TT. Cutaneous larva migrans complicated by Loffler syndrome. Arch Dermatol 2010; 146: 210-212. https://doi.org/10.1001/archdermatol.2009.392
  86. Sohn WM, Chai JY. Chapter 63. Anisakiosis (Anisakidosis). Part 4. Parasitic zoonoses. In eds, Palmer SR, Soulsby L, Torgerson P, Brown DWG. Oxford Textbook of Zoonoses: Biology, Clinical Practice, and Public Health Control (2nd ed.). Oxford Univ Press. London, UK. 2011, pp 776-788.
  87. Lim H, Jung BK, Cho J, Yooyen T, Shin EH, Chai JY. Molecular diagnosis of cause of anisakiasis in humans, South Korea. Emerg Infect Dis 2015; 21: 342-344. https://doi.org/10.3201/eid2102.140798
  88. Moore DAJ, Girdwood RWA, Chiodini PL. Treatment of anisakiasis with albendazole. Lancet 2002; 360: 54. https://doi.org/10.1016/S0140-6736(02)09333-9
  89. Pacios E, Arias-Diaz J, Zuloaga J, Gonzalez-Armengol J, Villarroel P, Balibrea JL. Albendazole for the treatment of anisakiasis ileus. Clin Infect Dis 2005; 41: 1825-1826. https://doi.org/10.1086/498309
  90. Baptista-Fernandes T, Rodrigues M, Castro I, Paixao P, PintoMarques P, Roque L, Belo S, Ferreira PM, Mansinho K, Toscano C. Human gastric hyperinfection by Anisakis simplex: a severe and unusual presentation and a brief review. Int J Infect Dis 2017; 64: 38-41. https://doi.org/10.1016/j.ijid.2017.08.012
  91. Guardone L, Armani A, Nucera D, Costanzo F, Mattiucci S, Bruschi F. Human anisakiasis in Italy: a retrospective epidemiological study over two decades. Parasite 2018; 25: 41. https://doi.org/10.1051/parasite/2018034
  92. Maggi P, Caputi-Lambrenghi O, Scardigno A, Scoppetta L, Saracino A, Valente M, Pastore G, Angarano G. Gastrointestinal infection due to Anisakis simplex in southern Italy. Eur J Epidemiol 2000; 16: 75-78. https://doi.org/10.1023/a:1007617002972
  93. Moschella CM, Mattiucci S, Mingazzini P, De Angelis G, Assenza M, Lombardo F, Monaco S, Paggi L, Modini C. Intestinal anisakiasis in Italy: case report. J Helminthol 2004; 78: 271-273. https://doi.org/10.1079/JOH2004237
  94. Gomez-Mateos M, Arrebola F, Navarro MC, Romero MC, Gonzalez JM, Valero A. Acute anisakiasis: pharmacological evaluation of various drugs. Dig Dis Sci 2021; 66: 105-113. https://doi.org/10.1007/s10620-020-06144-2
  95. McCracken RO. Efficacy of mebendazole and albendazole against Trichinella spiralis in mice. J Parasitol 1978; 64: 214-219. https://doi.org/10.2307/3279659
  96. Fourestie V, Bougnoux ME, Ancelle T, Liance M, Roudot-Thoraval F, Naga H, Pairon-Pennachioni M, Rauss A, Lejonc JL. Randomized trial of albendazole versus tiabendazole plus flubendazole during an outbreak of human trichinellosis. Parasitol Res 1988; 75: 36-41. https://doi.org/10.1007/BF00931188
  97. Cabie A, Bouchaud O, Houze S, Khuong MA, Ruggeri C, Ancelle T, Matheron S, Coulaud JP. Albendazole versus thiabendazole as therapy for trichinosis: a retrospective study. Clin Infect Dis 1996; 22: 1033-1035. https://doi.org/10.1093/clinids/22.6.1033
  98. Gottstein B, Pozio E, Nockler K. Epidemiology, diagnosis, treatment, and control of trichinellosis. Clin Microbiol Rev 2009; 22: 127-145. https://doi.org/10.1128/CMR.00026-08
  99. Dupouy-Camet J, Kociecka W, Bruschi F, Bolas-Fernandez F, Pozio E. Opinion on the diagnosis and treatment of human trichinellosis. Expert Opin Pharmacother 2002; 3: 1117-1130. https://doi.org/10.1517/14656566.3.8.1117
  100. Bruschi F, Murrell KD. Chapter 119. Trichinellosis. Part 6. Helminthic infections. In Strickland GT, Hunter GW eds, Hunter's Tropical Medicine and Emerging Infectious Diseases (8th ed.). Philadelphia, USA. Saunders. 2000, pp. 882-884.
  101. Lopez-Garcia ML,Torrado S, Torrado S, Martinez AR, Bolas F. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. Vet Parasitol 1998; 75: 209-219. https://doi.org/10.1016/S0304-4017(97)00177-5
  102. Kalaiselvan R, Mohanta GP, Madhusudan S, Manna PK, Manavalan R. Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques. Pharmazie 2007; 62: 604-607. https://doi.org/10.1691/ph.2007.8.6274
  103. Eid RK, Ashour DS, Essa EA, El Maghraby GM, Arafa MF. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella spiralis. Carbohyd Polym 2020; 232: 115826. https://doi.org/10.1016/j.carbpol.2019.115826
  104. Fernando SSE, Denham DA. The effects of mebendazole and fenbendazole on Trichinella spiralis in mice. J Parasitol 1976; 62: 874-876. https://doi.org/10.2307/3279176
  105. Sonnet JJ, Theinpont D. The treatment of trichinosis with mebendazole. Int J Clin Lab Med 1977; 32: 297-302. https://doi.org/10.1080/17843286.1977.11717878
  106. Levin ML. Treatment of trichinosis with mebendazole. Am J Trop Med Hyg 1983; 32; 980-983. https://doi.org/10.4269/ajtmh.1983.32.980
  107. Pozio E, Sacchini D, Sacchi L, Tamburrini A, Alberici F. Failure of mebendazole in the treatment of humans with Trichinella spiralis infection at the stage of encapsulating larvae. Clin Infect Dis 2001; 32: 638-642. https://doi.org/10.1086/318707
  108. Cheetham RF, Markus MB. Drug treatment of experimental Capillaria hepatica infection in mice. Parasitol Res 1991; 77: 517-520. https://doi.org/10.1007/BF00928420
  109. Choe GY, Lee HS, Seo JK, Chai JY, Lee SH, Eom KS, Chi JG. Hepatic capillariasis: first case report in Korea. Am J Trop Med Hyg 1993; 48: 610-625. https://doi.org/10.4269/ajtmh.1993.48.610
  110. Sawamura R, Fernandes MI, Peres LC, Galvao LC, Goldani HA, Jorge SM, de Melo Rocha G, de Souza NM. Hepatic capillariasis in children: report of 3 cases in Brazil. Am J Trop Med Hyg 1999; 61: 642-647. https://doi.org/10.4269/ajtmh.1999.61.642
  111. Dubey A, Bagchi A, Sharma D, Dey A, Nandy K, Sharma R. Hepatic capillariasis-drug targets. Infect Disord Drug Targ 2018; 18: 3-10. https://doi.org/10.2174/1871526517666170427124254
  112. Cross JH, Basaca-Sevilla V. Albendazole in the treatment of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1987; 18: 507-510.
  113. Lee SH, Hong ST, Chai JY, Kim WH, Kim YT, Song IS, Kim SW, Choi BI, Cross JH. A case of intestinal capillariasis in the Republic of Korea. Am J Trop Med Hyg 1993; 48: 542-546. https://doi.org/10.4269/ajtmh.1993.48.542
  114. Hong ST, Kim YT, Choe GY, Min YI, Cho SH, Kim JK, Kook J, Chai JY, Lee SH. Two cases of intestinal capillariasis in Korea. Korean J Parasitol 1994; 32: 43-48. http://dx.doi.org/10.3347/kjp.1994.32.1.43
  115. Bair MJ, Hwang KP, Wang TE, Liou TC, Lin SC, Kao CR, Wang TY, Pang KK. Clinical features of human intestinal capillariasis in Taiwan. World J Gastroenterol 2004; 10: 2391-2393. https://doi.org/10.3748/wjg.v10.i16.2391
  116. Soukhathammavong P, Sayasone S, Harimanana AN, Akkhavong A, Thammasack S, Phoumindr N, Choumlivong K, Choumlivong K, Keoluangkhot V, Phongmany S, Akkhavong K, Hatz C, Strobel M, Odermatt P. Three cases of intestinal capillariasis in Lao People's Democratic Republic. Am J Trop Med Hyg 2008; 79: 735-738. https://doi.org/10.4269/ajtmh.2008.79.735
  117. Rana SS, Bhasin DK, Bhatti HS, Gupta K, Gupta R, Nada R, Nagi B, Sinha SK, Singh K. Human intestinal capillariasis: diagnosis by jejunal fluid analysis obtained at enteroscopy and reversal of subtotal villous atrophy after treatment. Endoscopy 2009; 41 (suppl): 102-103. https://doi.org/10.1055/s-0028-1119609
  118. Sadaow L, Sanpool O, Intapan PM, Sukeepaisarnjaroen W, Prasongdee TK, Maleewong W. A hospital-based study of intestinal capillariasis in Thailand: clinical features, potential clues for diagnosis, and epidemiological characteristics of 85 patients. Am J Trop Med Hyg 2018; 98: 27-31. https://doi.org/10.4269/ajtmh.17-0465
  119. Alcantara AK, Uylangco CV, Cross JH. An obstinate case of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1985; 16: 410-413.
  120. Hoghooghi-Rad N, Maraghi S, Narenj-Zadeh A. Capillaria philippinensis infection in Khoozestan province, Iran: case report. Am J Trop Med Hyg 1987; 37: 135-137. https://doi.org/10.4269/ajtmh.1987.37.135
  121. Dronda F, Chaves F, Sanz A, Lopez-Velez R. Human intestinal capillariasis in an area of nonendemicity: case report and review. Clin Infect Dis 1993; 17: 909-912. https://doi.org/10.1093/clinids/17.5.909
  122. Mansour NS, Anis MH, Mikhail EM. Human intestinal capillariasis in Egypt. Trans R Soc Trop Med Hyg 1990; 84: 114. https://doi.org/10.1016/0035-9203(90)90398-X
  123. Hwang KP, Chen ER. Clinical studies on angiostrongyliasis cantonensis among children in Taiwan. Southeast Asian J Trop Med Public Health 1991; 22 (suppl): 194-199.
  124. Wang X, Huang H, Dong Q, Lin Y, Wang Z, Li F, Nawa Y, Yoshimura K. A clinical study of eosinophilic meningoencephalitis caused by angiostrongyliasis. Chin Med J 2002; 115: 1312-1315. https://doi.org/10.3760/j.issn:0366-6999.2002.09.007
  125. Chotmongkol V, Wongjitrat C, Sawadpanit K, Sawanyawisuth K. Treatment of eosinophilic meningitis with a combination of albendazole and corticosteroid. Southeast Asian J Trop Med Public Health 2004; 35: 172-174.
  126. Wang J, Qi H, Diao Z, Zheng X, Li X, Ma S, Ji A, Yin C. An outbreak of angiostrongyliasis cantonensis in Beijing. J Parasitol 2010; 96: 377-381. https://doi.org/10.1645/GE-2214-1
  127. Federspiel F, Skovmand S, Skarphedinsson S. Eosinophilic meningitis due to Angiostrongylus cantonensis in Europe. Int J Infect Dis 2020; 93: 28-39. https://doi.org/10.1016/j.ijid.2020.01.012
  128. Tsai HC, Liu YC, Kunin CM, Lee SS, Chen YS, Lin HH, Tsai TH, Lin WR, Huang CK, Yen MY, Yen CM. Eosinophilic meningitits caused by Angiostrongylus cantonensis: report of 17 cases. Am J Med 2001; 111: 109-114. https://doi.org/10.1097/MD.0000000000010975
  129. Chotmongkol V, Sawadpanitch K, Sawanyawisuth K, Louhawilai S, Limpawattana P. Treatment of eosinophilic meningitis with a combination of prednisolone and mebendazole. Am J Trop Med Hyg 2006; 74: 1122-1124. https://doi.org/10.4269/ajtmh.2006.74.1122
  130. Leone S, De Marco M, Ghirga P, Nicastri E, Esposito M, Narciso P. Eosinophilic meningitis in a returned traveler from Santo Domingo: case report and review. J Travel Med 2007; 14: 407-410. https://doi.org/10.1111/j.1708-8305.2007.00152.x
  131. Hermes CC, Benvegnu E, Costa MM, Rodriguez R, Vieira MIB. Abdominal angiostrongyliasis: pathologic findings in Swiss mice infected with different doses of Angiostrongylus costaricensis. J Helminthol 2020; 94: e169. https://doi.org/10.1017/S0022149X20000516
  132. Dekumyoy P, Watthanakulpanich D. Chapter 121. Gnathostomiasis. Part 6. Helminthic Infections. In Ryan ET, Hill DR, Solomon T, Aronson NE, Endy TP eds, Hunter's Tropical Medicine and Emerging Infectious Diseases, 10th ed. Edinburgh, Scotland. Elsevier. 2020, pp 888-890.
  133. Kraivichian K, Kulkumthorn M, Yingyourd P, Akarabovorn P, Paireepai CC. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992; 86: 418-421. https://doi.org/10.1016/0035-9203(92)90248-B
  134. Nontasut P, Bussaratid V, Chullawichit S, Charoensook N, Visetsuk K. Comparison of ivermectin and albendazole treatment for gnathostomiasis. Southeast Asian J Trop Med Public Health 2000; 31: 374-377. https://www.tm.mahidol.ac.th/seameo/2000_31_2/29-2490.pdf
  135. Nontasut P, Claesson BA, Dekumyoy P, Pakdee W, Chullawichit S. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. Southeast Asian J Trop Med Public Health 2005; 36: 650-652.
  136. Kraivichian K, Nuchprayoon S, Sitichalernchai P, Chaicumpa W, Yentakam S. Treatment of cutaneous gnathostomiasis with ivermectin. Am J Trop Med Hyg 2004; 71: 623-628. https://doi.org/10.4269/ajtmh.2004.71.623
  137. Haddad Junior V, Oliveira IF, Bicudo NP, Marques MEA. Gnathostomiasis acquired after consumption of raw freshwater fish in the Amazon region: a report of two cases in brazil. Rev Soc Bras Med Trop 2021; 54: e20200127. https://doi.org/10.1590/0037-8682-0127-2020
  138. Chai JY, Han ET, Shin EH, Park JH, Chu JP, Hirota M, Nakamura-Uchiyama F, Nawa Y. An outbreak of gnathostomiasis among Korean emigrants in Myanmar. Am J Trop Med Hyg 2003; 69: 67-73. https://doi.org/10.4269/ajtmh.2003.69.67
  139. Vanegas ES, Cendejas RF, Mondragon A. A 41-year-old woman with migratory panniculitis. Am J Trop Med Hyg 2014; 90: 786-787. https://doi.org/10.4269/ajtmh.13-0318
  140. Sharma C, Piyaphanee W, Watthanakulpanich D. Case report: clinical features of intermittent migratory swelling caused by gnathostomiasis with complete follow-up. Am J Trop Med Hyg 2017; 97: 1611-1615. https://doi.org/10.4269/ajtmh.17-0239
  141. Herman JS, Chiodini PL. Gnathostomiasis, another emerging imported disease. Clin Microbiol Rev 2009; 22: 484-492. https://doi.org/10.1128/CMR.00003-09
  142. Raharisoa A, Izri A, Andrianjafy RL, Rajaona RA, Marteau A, Durand R, Akhoundi M. Autochthonous gnathostomiasis in Madagascar. Emerg Infect Dis 2020; 26: 1875-1877. https://doi.org/10.3201/eid2608.200383
  143. Eberhard ML, Busillo C. Human Gongylonema infection in a resident of New York City. Am J Trop Med Hyg 1999; 61: 51-52. https://doi.org/10.4269/ajtmh.1999.61.51
  144. Wilson ME, Lorente CA, Allen JE, Eberhard ML. Gongylonema infection of the mouth in a resident of Cambridge, Massachusetts. Clin Infect Dis 2001; 32: 1378-1380. https://doi.org/10.1086/319991
  145. Ayala MA, Yencha MW. Gongylonema a parasitic nematode of the oral cavity. Arch Otolaryngol Head Neck Surg 2012; 138: 1082-1084. https://doi.org/10.1001/2013.jamaoto.386
  146. Waisberg V, Lima WDS, Vasconcelos-Santos DV. Intraocular Gongylonema infection: first case in humans. Ocul Immunol Inflam 2016; 26: 595-597. https://doi.org/10.1080/09273948.2016.1232739
  147. Xiaodan L, Zhensheng W, Ying H, Hongwei L, Jiangqiu J, Peiru Z, Sha S, Zhimin Y. Gongylonema pulchrum infection in the human oral cavity: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 125: e49-e53. https://doi.org/10.1016/j.oooo.2017.11.019
  148. Libertin CR, Reza M, Peterson JH, Lewis J, Hata DJ. Human Gongylonema pulchrum infection: esophageal symptoms and need for prolonged albendazole therapy. Am J Trop Med Hyg 2017; 96: 873-875. https://doi.org/10.4269/ajtmh.16-0852
  149. Kudo N, Kubota H, Gotoh H, Ishida H, Ikadai H, Oyamada T. Efficacy of thiabendazole, mebendazole, levamisole and ivermectin against gullet worm, Gongylonema pulchrum: in vitro and in vivo studies. Vet Parasitol 2008; 151: 46-52. https://doi.org/10.1016/j.vetpar.2007.10.005
  150. do Vale B, Lopes AP, Fontes MC, Silvestre M, Cardoso L, Coelho AC. Thelaziosis due to Thelazia callipaeda in Europe in the 21st century-a review. Vet Parasitol 2019; 275; 108957. https://doi.org/10.1016/j.vetpar.2019.108957
  151. Calero-Bernal R, Sanchez-Murillo JM, Alarcon-Elbal PM, Sanchez-Moro J, Latrofa MS, Dantas-Torres F, Otranto D. Resolution of canine ocular thelaziosis in avermectin-sensitive Border Collies from Spain. Vet Parasitol 2014; 200: 203-206. https://doi.org/10.1016/j.vetpar.2013.12.014
  152. Sharma M, Das D, Bhattacharjee H, Islam S, Deori N, Bharali G, Tomar S, Bhola P, Deka A. Human ocular thelaziasis caused by gravid Thelazia callipaeda-a unique and rare case report. Ind J Ophthalmol 2019; 67: 282-285. https://doi.org/10.4103/ijo.IJO_1110_18
  153. Mullner A, Helfer A, Kotlyar D, Oswald J, Efferth T. Chemistry and pharmacology of neglected helminthic diseases. Curr Med Chem 2011; 18: 767-789. https://doi.org/10.2174/092986711794480096
  154. Eberhard ML, Brandt FH, Ruiz-Tiben E, Hightower A. Chemoprophylactic drug trials for treatment of dracunculiasis using the Dracunculus insignis-ferret model. J Helminthol 1990; 64: 79-86. https://doi.org/10.1017/S0022149X00011962
  155. Escobedo F, Penagos P, Rodriguez J, Sotelo J. Albendazole therapy for neurocysticercosis. Arch Intern Med 1987; 147: 738-741. https://doi.org/10.1001/archinte.1987.00370040120021
  156. Sotelo J, Escobedo F, Oenagos P. Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol 1988; 45: 532-534. https://doi.org/10.1001/archneur.1988.00520290064015
  157. Alarcon F, Escalante L, Duefias G, Montalvo M, Roman M. Neurocysticercosis. Short course of treatment with albendazole. Arch Neurol 1989: 46: 1231-1236. https://doi.org/10.1001/archneur.1989.00520470099034
  158. Sotelo J, Jung H. Pharmacokinetic optimization of the treatment of neurocysticercosis. Clin Pharmacokinet 1998; 34: 503-515. https://doi.org/10.2165/00003088-199834060-00006
  159. Garcia HH, Evans CA, Nash TE, Takayanagui OM, White AC Jr, Botero D, Rajshekhar V, Tsang VC, Schantz PM, Allan JC, Flisser A, Correa D, Sarti E, Friedland JS, Martinez SM, Gonzalez AE, Gilman RH, Del Brutto OH. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002; 15: 747-756. https://doi.org/10.1128/CMR.15.4.747-756.2002
  160. del Brutto OH, Sotelo J. Albendazole therapy for subarachnoid and ventricular cysticercosis-case report. J Neurosurg 1990; 72: 816-817. https://doi.org/10.3171/jns.1990.72.5.0816
  161. Arroyo G, Bustos JA, Lescano AG, Gonzales I, Saavedra H, Rodriguez S, Pretell EJ, Bonato PS, Lanchote VL, Takayanagui OM, Horton J, Gonzalez AE, Gilman RH, Garcia HH, Cysticercosis Working Group in Peru. Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis. Clin Infect Dis 2019; 69: 1996-2002. https://doi.org/10.1093/cid/ciz085
  162. Schmidt DK, Jordaan HF, Schneider JW, Cilliers J. Cerebral and subcutaneous cysticercosis treated with albendazole. Int J Dermatol 1995; 34: 574-579. https://doi.org/10.1111/j.1365-4362.1995.tb02959.x
  163. Surve A, Goel S, Bajaj MS, Pujari A. Extraocular muscle cysticercosis: never skip steroids. BMJ Case Rep 2018; 2018: 1-2. https://10.1136/bcr-2017-223356
  164. Palomares-Alonso F, Toledo A, Palencia Hernandez G, Jung-Cook H, Fleury A. Effect of dexamethasone on albendazole cysticidal activity in experimental cysticercosis by Taenia crassiceps in BALB/c mice: in vivo and in vitro evaluation. Exp Parasitol 2020; 208: 107801. https://doi.org/10.1016/j.exppara.2019.107801
  165. Cook GC. Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy. Parasitol Today 1990; 6: 133-136. https://doi.org/10.1016/0169-4758(90)90232-S
  166. Heath DD, Christie MJ, Chevis RAF. The lethal effect of mebendazole on secondary Echinococcus granulosus, cysticerci of Taenia pisiformis and tetrathyridia of Mesocestoides corti. Parasitology 1975; 70: 273-285. https://doi.org/10.1017/S0031182000049738
  167. Francisca PA, Javier LF, Guadalupe PH, Fernanda GM, Nelly C, Helgi JC, Iliana GH, Susana RTI. Cysticidal activity of praziquantel-mebendazole combination: in vitro and in vivo studies. Acta Trop 2019; 202: 105238. https://doi.org/10.1016/j.actatropica.2019.105238
  168. Hemphill A, Stadelmann B, Rufener R, Spiliotis M, Boubaker G, Muller J, Muller N, Gorgas D, Gottstein B. Treatment of echinococcosis: albendazole and mebendazole-what else? Parasite 2014; 21: 70. https://doi.org/10.1051/parasite/2014073
  169. Velasco-Tirado V, Alonso-Sardon M, Lopez-Bernus A, RomeroAlegria A, Burguillo FJ, Muro A, Carpio-Perez A, Munoz Bellido JL, Pardo-Lledias J, Cordero M, Belhassen-Garcia M. Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis 2018; 18: 306. https://doi.org/10.1186/s12879-018-3201-y
  170. Saimot AG, Meulemans A, Cremieux AC, Giovanangeli MD, Hay JM, Delaitre B, Coulaud JP. Albendazole as a potential treatment for human hydatidosis. Lancet 1983; 322: 652-656. https://doi.org/10.1016/S0140-6736(83)92533-3
  171. Morris DL, Dykes PW, Dickson B, Marriner SE, Bogan JA, Burrows FGO. Albendazole in hydatid disease. Br Med J 1983; 286: 103-104. https://doi.org/10.1136/bmj.286.6359.103-a
  172. Todorov T, Vutova K, Mechkov G, Georgiev P, Petkov D, Tonchev Z, Nedelkov G. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. Ann Trop Med Parasitol 1992; 86: 59-66. https://doi.org/10.1080/00034983.1992.11812631
  173. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 1997; 64: 79-93. https://doi.org/10.1016/S0001-706X(96)00640-7
  174. Horton J. Albendazole for the treatment of echinococcosis. Fundam Clin Pharmacol 2003; 17: 205-212. https://doi.org/10.1046/j.1472-8206.2003.00171.x
  175. Falagas ME, Bliziotis IA. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. Am J Med Sci 2007; 334: 171-179. https://doi.org/10.1097/MAJ.0b013e31814252f8
  176. Mohamed AE, Yasawy MI, Karawi MAA. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology 1998; 45: 1690-1694.
  177. Cobo F, Yarnoz C, Sesma B, Fralle P, Aizcorbe M, Trujillo R, Diaz-de-Liano A, Ciga MA. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by Echinococcus granulosus. Trop Med Int health 1998; 3: 462-466. https://doi.org/10.1046/j.1365-3156.1998.00257.x
  178. Mueller PR, Dawson SL, Ferrucci JT Jr, Nardi GL. Hepatic echinococcal cyst: successful percutaneous drainage. Radiology 1985; 155: 627-628. https://doi.org/10.1148/radiology.155.3.3890001
  179. Khuroo MS, Dar MY, Yattoo GN, Zargar SA, Javaid G, Khan BA, Boda MI. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Gastroenterology 1993; 104: 1452-1459. https://doi.org/10.1016/0016-5085(93)90355-G
  180. Khuroo MS, Wani NA, Javaid G, Khan BA, Yattoo GN, Shah AH, Jeelani SG. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med 1997; 337: 881-887. https://doi.org/10.1056/NEJM199709253371303
  181. Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003; 37: 1073-1083. https://doi.org/10.1086/378275
  182. Ormeci N, Kalkan C, Karakaya F, Erden A, Kose KS, Tuzun AE, Deda X. Percutaneous treatment with the Ormeci technique of cystic echinococcosis: experience of single center. Gastroenterol Hepatol Open Access 2020; 11: 223-230. https://doi.org/10.15406/ghoa.2020.11.00443
  183. Heath DD, Chevis RAF. Mebendazole and hydatid cysts. Lancet 1974; 304: 218-219. https://doi.org/10.1016/S0140-6736(74)91517-7
  184. Bekhti A, Schaaps JP, Capron M, Dessaint JP, Santoro F, Capron A. Treatment of hepatic hydatid disease with mebendazole: preliminary results in four cases. Br Med J 1977; 2: 1047-1051. https://doi.org/10.1136/bmj.2.6094.1047
  185. Verheyen A. Echinococcus granulosus: the influence of mebendazole therapy on the ultrastructural morphology of the germinal layer of hydatid cysts in humans and mice. Z Parazitenkd 1982; 67: 55-65. https://doi.org/10.1007/BF00929514
  186. Gocmen A, Toppare MF, Kiper N. Treatment of hydatid disease in childhood with mebendazole. Eur Respir J 1993; 6: 253-257. https://erj.ersjournals.com/content/6/2/253
  187. Salto E, Juarez E, Roiz MP, Abad J. Combined chemotherapy (mebendazole plus praziquantel) in patients with hydatidosis. Enferm Infecc Microbiol Clin 1991; 9: 527-529 (in Spanish). https://europepmc.org/article/med/1822703
  188. Vutova K, Mechkov G, Vachkov P, Petkov R, Georgiev P, Handjiev S, Ivanovh A, Todorov T. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann Trop Med Parasitol 1999; 93: 357-365. https://doi.org/10.1080/00034983.1999.11813432
  189. Ammann RW, Fleiner-Hoffmann A, Grimm F, Eckert J. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 1998; 29: 994-998. https://doi.org/10.1016/S0168-8278(98)80129-3
  190. Addiss D, Gamble CL, Garner P, Gelband H, Ejere HOD, Critchley JA. Albendazole for lymphatic filariasis. Cochrane Datab Syst Rev 2005; 4: CD003753. https://doi.org/10.1002/14651858.CD003753.pub3
  191. Kimura E, Penaia L, Spears GFS. The efficacy of annual single-dose treatment with diethylcarbamazine citrate against diurnally subperiodic bancroftian filariasis in Samoa. Bull World Health Organ 1985; 63: 1097-1106.
  192. Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 1999; 15: 382-386. https://doi.org/10.1016/S0169-4758(99)01486-6
  193. Moulia-Pelat JP, Glaziou P, Weil GJ, Nguyen LN, Gaxotte P, Nicolas L. Combination ivermectin plus diethylcarbamazine, a new effective tool for control lymphatic filariasis. Trop Med Parasitol 1995; 46: 9-12. https://europepmc.org/article/med/7631132
  194. Jayakody RL, De Silva CSS, Weerasinghe WMT. Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Trop Biomed 1993; 10: 19-24.
  195. Addiss DA, Beach MJ, Streit TG, Lutwick S, LeConte FH, Lafontant JG, Hightower AW, Lammie PJ. Randomised placebo-controlled comparison of ivermectin and albendazole and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997; 350: 480-484. https://doi.org/10.1016/S0140-6736(97)02231-9
  196. Ismail MM, Jayakody RL, Weil GJ, Nirmalan N, Jayasinghe KS, Abeyewickrema W, Rezvi Sheriff MH, Rajaratnam HN, Amarasekera N, de Silva DC, Michalski ML, Dissanaike AS. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1998; 92: 94-97. https://doi.org/10.1016/S0035-9203(98)90972-5
  197. Horton J. The development of albendazole for lymphatic filariasis. Ann Trop Med Parasitol 2009; 103(suppl): 33-40. https://doi.org/10.1179/000349809X12502035776595
  198. Pion SDS, Chesnais CB, Awaca-Uvon NP, Vlaminck J, Abdou A, Kunyu-Shako B, Kuyangisa Simuna G, Tambwe JP, Weil GJ, Boussinesq M. The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Democratic Republic of Congo. PLoS Negl Trop Dis 2020; 14: e0008322. https://doi.org/10.1371/journal.pntd.0008322
  199. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997; 75: 491-503.
  200. Shenoy RK, Dalia S, John A, Suma TK, Kumaraswami V. Treatment of the microfilaraemia of asymptomatic brugian filariasis with single doses of ivermectin, diethylcarbamazine or albendazole, in various combinations. Ann Trop Med Parasitol 1999; 93: 643-651. https://doi.org/10.1080/00034983.1999.11813467
  201. Fischer P, Djuardi Y, Ismid IS, Ruckert P, Bradley M, Supali T. Long-lasting reduction of Brugia timori microfilariae following a single dose of diethylcarbamazine combined with albendazole. Trans R Soc Trop Med Hyg 2003; 97: 446-448. https://doi.org/10.1016/S0035-9203(03)90086-1
  202. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005; 6: 179-200. https://doi.org/10.1517/14656566.6.2.179
  203. Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis 2005; 5: 514-523. https://doi.org/10.1016/S1473-3099(05)70192-4
  204. Critchley J, Addiss D, Ejere H, Gamble C, Garner P, Helband H. Albendazole for the control and elimination of lymphatic filariasis: systematic review. Trop Med Int Health 2005; 10: 818-825. https://doi.org/10.1111/j.1365-3156.2005.01458.x
  205. Macfarlane CL, Budhahoki SS, Johnson S, Richardson M, Garner P. Albendazole along or in combination with microfilaricidal drugs for lymphatic filariasis (Review). Cochrane Datab Syst Rev 2019; 1: CD003753. https://doi.org/10.1002/14651858.CD00-3753.pib4
  206. Kar SK, Dwibedi B, Das BK, Agrawala BK, Ramachandran CP, Horton J. Lymphatic pathology in asymptomatic and symptomatic children with Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment. PLoS Negl Trop Dis 2017; 11: e0005631. https://doi.org/10.1371/journal.pntd.0005631
  207. Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Meite A, Koudou BG, Weil GJ, King CL, Murry DJ. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Cote d'Ivoire. PLoS Negl Trop Dis 2019; 13: e0007325. https://doi.org/10.1371/journal.pntd.0007325
  208. Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, Rahi M, Somani RK, Suryaprakash MK, Dwivedi GP, Weil GJ. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop Dis 2021; 15: e0009069. https://doi.org/10.1371/journal.pntd.0009069
  209. Turner JD, Mad S, Debrah AY, Muehlfeld J, Pfarr K, McGarry HF, Adjei O, Taylor MJ, Hoerauf A. A randomized, doubleblind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006; 42: 1081-1089. https://doi.org/10.1086/501351
  210. Sarma RVSN, Vallishayee RS, Rao RSN, Prabhakar R, Tripathy SP. Use of mebendazole in combination with DEC in bancroftian filariasis. Indian J Med Res 1988; 87: 579-583. https://eprints.nirt.res.in/242/
  211. Awadzi K, Edwards G, Duke BOL, Opoku NO, Attah SK, Addy ET, Ardrey AE, Quartey BT. The co-administration of ivermectin and albendazole-safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann Trop Med Parasitol 2003; 97: 165-178. https://doi.org/10.1179/000349803235001697
  212. Awadzi K, Hero M, Opoku O, Buttner DW, Gilles HM. The chemotherapy of onchocerciasis. XV. Studies with albendazole. Trop Med Parasitol 1991; 42: 356-360. https://europepmc.org/article/med/1796233
  213. Cline BL, Hernandez JL, Mather FJ, Bartholomew R, Maza SN, Rodulfo S, Welborn CA, Eberhard ML, Convit J. Albendazole in the treatment of onchocerciasis: double-blind clinical trial in Venezuela. Am J Trop Med Hyg 1992; 47: 512-520. https://doi.org/10.4269/ajtmh.1992.47.512
  214. Awadzi K, Addy ET, Opoku NO, Plenge-Bonig A, Buttner DW. The chemotherapy of onchocerciasis. XX. Ivermectin in combination with albendazole. Trop Med Parasitol 1995; 46: 213-220. https://europepmc.org/article/med/8826100
  215. Batsa Debrah L, Klarmann-Schulz U, Osei-Mensah J, Dubben B, Fischer K, Mubarik Y, Ayisi-Boateng NK, Ricchiuto A, Fimmers R, Konadu P, Nadal J, Gruetzmacher B, Weil G, Kazura JW, King CL, Debrah AY, Hoerauf A. Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: a randomized, open-label, clinical trial. Clin Infect Dis 2020; 71: 933-943. https://doi.org/10.1093/cid/ciz889
  216. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010; 376: 1175-1185. https://doi.org/10.1016/S0140-6736(10)60586-7
  217. Klarmann-Schulz U, Specht S, Debrah AY, Batsa L, Ayisi-Boateng NK, Osei-Mensah J, Mubarik Y, Konadu P, Ricchiuto A, Fimmers R, Arriens S, Dubben B, Ford L, Taylor M, Hoerauf A. Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open-label, pilot trial. PLoS Negl Trop Dis 2017; 11: e0005156. https://doi.org/10.1371/journal.pntd.0005156
  218. Fischer PU, King CL, Jacobson JA, Weil GJ. Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. PLoS Negl Trop Dis 2017; 11: e0005163. https://doi.org/10.1371/journal.pntd.0005163
  219. Duke BOL. Mebendazole-ineffective against Onchocerca volvulus. Trans R Soc Trop Med Hyg 1974; 68: 172. https://doi.org/10.1016/0035-9203(74)90199-0
  220. Maertens K, Wery M. Effect of mebendazole and levamisole on Onchocerca volvulus and Dipetalonema perstans. Trans R Soc Trop Med Hyg 1975; 69: 359-360. https://doi.org/10.1016/0035-9203(75)90134-0
  221. Taylor HR, Awadzi K, George T, Schulz-Key H, Murphy RP. Fluorescein angiographic studies of mebendazole treatment for onchocerciasis. Trop Med Parasitol 1985; 36: 7-11. https://europepmc.org/article/med/4001769
  222. Rivas-Alcala AR, Greene BM, Taylor HR, Domiguez-Vazquez A, Ruvalcaba-Macias AM, Lugo-Pfeiffer C, Mackenzie CD, Beltran F. Chemotherapy of onchocerciasis: a controlled comparison of mebendazole, levamisole, and diethylcarbamazine. Lancet 1981; 318: 485-490. https://doi.org/10.1016/S0140-6736(81)90880-1
  223. Awadzi K, Schulz-Key H, Howells RE, Haddock DRW, Gilles HM. The chemotherapy of onchocerciasis. VIII. Levamisole and its combination with the benzimidazoles. Ann Trop Med Parasitol 1982; 76: 459-473. https://doi.org/10.1080/00034983.1982.11687567
  224. Awadzi K. Research notes from the Onchocerciasis Chemotherapy Research Centre, Ghana. Ann Trop Med Parasitol 1997; 91: 703-711. https://doi.org/10.1080/00034983.1997.11813193
  225. Awadzi K, Edwards G, Opoku NO, Ardrey AE, Favager S, Addy ET, Attah SK, Yamuah LK, Quartey BT. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann Trop Med Parasitol 2004; 98: 595-614. https://doi.org/10.1079/000349804225021370
  226. Klion AD, Massougbodji A, Horton J, Ekoue S, Lanmasso T, Ahouissou NL, Nutman TB. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis 1993; 168: 202-206. https://doi.org/10.1093/infdis/168.1.202
  227. Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis 1999; 29: 680-682. https://doi.org/10.1086/598654
  228. Arrey-Agbor DB, Nana-Djeunga HC, Mogoung-Wafo AE, Mafo M, Danwe C, Kamgno J. Case report: probable case of spontaneous encephalopathy due to loiasis and dramatic reduction of Loa loa microfilaraemia with prolonged repeated courses of albendazole. Am J Trop Med Hyg 2018; 99: 112-115. https://doi.org/10.4269/ajtmh.17-0664
  229. Gobbi F, Buonfrate D, Tamarozzi F, Degani M, Angheben A, Bisoffi Z. Efficacy of high-dose albendazole with ivermectin for treating imported loiasis, Italy. Emerg Infect Dis 2019; 25: 1574-1576. https://doi.org/10.3201/eid2508.190011
  230. Tabi TE, Befidi-Mengue R, Nutman TB, Horton J, Folefack A, Pensia E, Fualem R, Fogako J, Gwanmesia P, Quakyi I, Leke R. Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. Am J Trop Med Hyg 2004; 71: 211-215. https://doi.org/10.4269/ajtmh.2004.71.211
  231. Tsague-Dongmo L, Kamgno J, Pion SDS, Moyou-Somo R, Boussinesq M. Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. Ann Trop Med Parasitol 2002; 96: 707-715. https://doi.org/10.1179/000349802125001933
  232. Richard-Lenoble D, Komblia M, Burnier I, Maganga ML. Filariasis in Gabon: treatment with mebendazole of filariasis due to Mansonella perstans and Loa loa. Bull Soc Pathol Rxot Filial 1985; 78: 485-491 (in French). https://europepmc.org/article/med/3865739
  233. Burchard GD, Kern P. Failure of high dose mebendazole as a microfilaricide in patients with loiasis. Trans R Soc Trop Med Hyg 1987; 81: 420. https://doi.org/10.1016/0035-9203(87)90156-8
  234. Van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in the treatment of filariasis due to Loa loa and Mansonella perstans. Ann Trop Med Parasitol 1987; 81: 275-282. https://doi.org/10.1080/00034983.1987.11812120
  235. Kamgno J, Roussinesq M. Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia. Parasite 2002; 9: 59-63. https://doi.org/10.1051/parasite/200209159
  236. Pion S, Chesnais C. Loiasis. In Marcondes CB ed, Arthropod Borne Diseases. Springer, Switzerland. 2017, pp 427-444. https://doi.org/10.1007/978-3-319-13884-8_27
  237. Ta-Tang TH, Crainey JL, Post RJ, Lutz SLB, Rubio JM. Mansonellosis: current perspectives. Res Rep Trop Med 2018; 9: 9-24. https://doi.org/10.2147/RRTM.S125750
  238. Puente S, Lago M, Subirats M, Sanz-Esteban I, Arsuaga M, Vicente B, Alonso-Sardon M, Behlhassen-Garcia M, Muro A. Imported Mansonella perstans infection in Spain. Infect Dis Poverty 2020; 9: 105. https://doi.org/10.1186/s40249-020-00729-9
  239. Van den Enden E, Van Gompel A, Vervoort T, Van der Stuyft P, Van den Ende J. Mansonella perstans filariasis: failure of albendazole treatment. Ann Soc Belge Med Trop 1992; 72: 215-218. http://dspace.itg.be/bitstream/handle/10390/4511/1992asbm0215.pdf?sequence=1
  240. Lipani F, Caramello P, Biglino A, Sacchi C. Albendazole for the treatment of Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 1997; 91: 221. https://doi.org/10.1016/S0035-9203(97)90232-7
  241. Duong TH, Kombila M, Ferrer A, Nguiri C, Richard-Lenoble D. Decrease in Mansonella perstans microfilaraemia after albendazole treatment. Trans R Soc Trop Med Hyg 1998; 92: 459. https://doi.org/10.1016/S0035-9203(98)91093-8
  242. Asio SM, Simonsen PE, Onapa AW. Mansonella perstans: safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination. Ann Trop Med Parasitol 2009; 103: 31-37. https://doi.org/10.1179/136485909X384929
  243. Asgeirsson H, Harling A, Botero-Kleiven S. Successful treatment of 2 imported cases of Mansonella perstans infection. PLoS Negl Trop Dis 2017; 11: e0005452. https://doi.org/10.1371/journal.pntd.005452
  244. Debrah LB, Phillips RO, Pfarr K, Klarmann-Schulz U, Opoku VS, Nausch N, Owusu W, Mubarik Y, Sander AL, Lammer C, Ritter M, Layland LE, Jacobsen M, Debrah AY, Hoerauf A. The efficacy of doxycycline treatment on Mansonella perstans infection: an open-label, randomized trial in Ghana. Am H Trop Med Hyg 2019; 101: 84-92. https://doi.org/10.4269/ajtmh.18-0491
  245. Wahlgren M. The successful treatment of Dipetalonema perstans filariasis with mebendazole. Ann Trop Med Parasitol 1982; 76: 557-559. https://doi.org/10.1080/00034983.1982.11687580
  246. Wahlgren M, Frolov I. Treatment of Dipetalonema perstans infections with mebendazole. Trans R Soc Trop Med Hyg 1983; 77: 422. https://doi.org/10.1016/0035-9203(83)90179-7
  247. Bregani ER, Rovellini A, Mbaidoum N, Magnini MG. Comparison of different anthelmintic drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 2006; 100: 458-463. https://doi.org/10.1016/j.trstmh.2005.07.009
  248. Simon F, Siles-Lucas M, Morchon R, Gonzalez-Miguel J, Mellado I, Carretan E, Montoya-Alonso JA. Human and animal dirofilariasis: the emergence of a zoonotic mosaic. Clin Microbiol Rev 2012; 25: 507-544. https://doi.org/10.1128/CMR.00012-12
  249. GheorghiTa MI, ForTofoiu MC, Dumitrescu CI, Dumitrescu D, Camen A, Margaritescu C. Intramuscular human Dirofilaria repens infection of the temporal region-case report and review of literature. Rom J Morphol Embryol 2017; 58: 585-592.
  250. Ermakova L, Nagorny S, Pschenichnaya N, Ambalov Y. Clinical and laboratory features of human dirofilariasis in Russia. IDCases 2017; 9: 112-115. https://doi.org/10.1016/j.idcr.2017.07.006
  251. Moskvina TV, Ermolenko AV. Dirofilariasis in Russian Federation: a big problem with large distribution. Russ Open Med J 2018; 7: e0102. https:/doi.org/10.15275/rusomj.2018.0102
  252. Keiser J, Engels D, Buscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005; 14: 1513-1526. https://doi.org/10.1517/13543784.14.12.1513
  253. Mas-Coma S, Velero MA, Bargues MD. Fascioliasis. Adv Exp Med Biol 2019; 1154: 71-103. https://doi.org/10.1007/978-3-030-18616-6_4
  254. Ronald NC, Crag TM, Bell RR. A controlled evaluation of albendazole against natural infections with Fasciola hepatica and Fascioloides magna in cattle. Am J Vet Res 1979; 40: 1299-1300.
  255. Fetterer R, Rew RS, Knight R. Comparative efficacy of albendazole against Fasciola hepatica in sheep and calves: relationship to serum drug metabolite levels. Vet Parasitol 1982; 11: 309-316. https://doi.org/10.1016/0304-4017(82)90099-1
  256. Laird PP, Boray JC. Human fascioliasis successfully treated with triclabendazole. Aust N Z J Med 1992; 22: 45-47. https://doi.org/10.1111/j.1445-5994.1992.tb01708.x
  257. Apt W, Aguilera X, Vega F, Miranda C, Zulantay I, Perez C, Gabor M, Apt P. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52: 532-535. https://doi.org/10.4269/ajtmh.1995.52.532
  258. Zali AH, Ghaziani T, Shahraz S, Hekmatdoost A, Radmehr A. Liver, spleen, pancreas and kidney involvement by human fascioliasis: imaging findings. BMC Gastroenterol 2004; 4: 15. https://doi.org/10.1186/1471-230X-4-15
  259. Saba R, Korkmaz M, Inan D, Mamikoglu L, Turhan O, Gunseren F, Cevikol C, Kabaalioglu A. Human fascioliasis. Human fascioliasis. Clin Microbiol Infect 2004; 10: 385-387. https://doi.org/10.1111/j.1469-0691.2004.00820.x
  260. Robinson MW, Lawson J, Trudgett A, Hoey EM, Fairweather I. The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol Res 2004; 92: 205-210. https://doi.org/10.1007/s00436-003-1003-6
  261. Arauco R, Zetola NM, Calderon F, Seas C. Human fascioliasis: a case of hyperinfection and an update for clinicians. Foodborne Pathog Dis 2007; 4: 305-312. https://doi.org/10.1089/fpg.2007.0001
  262. Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of clonorchiasis sinensis. Chin Med J 1991; 104: 27-31. https://europepmc.org/article/med/1879192
  263. Jaroonvesma N, Charoenlarp K, Cross JH. Treatment of Opisthorchis viverrini with mebendazole. Southeast Asian J Trop Med Public Health 1981; 12: 595-597. https://europepmc.org/article/med/7344109
  264. Pungpark S, Radomyos P, Radomyos B, Bunnag D. Albendazole treatment of minute intestinal fluke infections and opisthorchiasis. Parasitol Int 1998; 47 (suppl): 241. https://doi.org/10.1016/S1383-5769(98)80658-2
  265. Cross JH, Basaca-Sevilla V. Studies on Echinostoma ilocanum in the Philippines. Southeast Asian J Trop Med Public Health 1986; 17: 23-27. https://europepmc.org/article/med/3090713
  266. Edlind TD, Hang TL, Chakraborty PR. Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro. J Infect Dis 1990; 162: 1408-1411. https://doi.org/10.1093/infdis/162.6.1408
  267. Meloni BP, Thompson RCA, Reynoldson JA, Seville P. Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans R Soc Trop Med Hyg 1990; 84: 375-379. https://doi.org/10.1016/0035-9203(90)90324-8
  268. Reynoldson JA, Thompson RCA, Meloni BP. In vivo efficacy of albendazole against Giardia duodenalis in mice. Parasitol Res 1991; 77: 325-328. https://doi.org/10.1007/BF00930909
  269. Barr SC, Bowman DD, Heller RL, Erb HN. Efficacy of albendazole against giardiasis in dogs. Am J Vet Res 1993; 54: 926-928. https://europepmc.org/article/med/8323064
  270. Oxberry ME, Thompson RCA, Reynoldson JA. Evaluation of the effects of albendazole and metronidazole on the ultrastructure of Giardia duodenalis, Trichomonas vaginalis and Spironucleus muris using transmission electron microscopy. Int J Parasitol 1994; 24: 695-703. https://doi.org/10.1016/0020-7519(94)90123-6
  271. Cheng-i W. Parasitic diarrhoeas in China. Parasitol Today 1988; 4: 284-287. https://doi.org/10.1016/0169-4758(88)90020-8
  272. Hall A, Nahar Q. Albendazole as a treatment for infection with Giardia duodenalis in children in Bangladesh. Trans R Soc Trop Med Hyg 1993; 87: 84-86. https://doi.org/10.1016/0035-9203(93)90435-S
  273. Escobedo AA, Hanevik K, Almirall P, Cimerman S, Alfonso M. Management of chronic Giardia infection. Expert Rev Anti Infect Ther 2014; 12: 1143-1157. https://doi.org/10.1586/14787210.2014.942283
  274. Cacopardo B, Patamia I, Bonaccorso V, Paola O, Bonforte S, Brancati G. Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis. Clin Ther 1995; 146: 761-767 (in Italian). https://europepmc.org/article/med/8681495
  275. Morch K, Hanevik K, Robertson LJ, Strand EA, Langeland N. Treatment-ladder and genetic characterization of parasites in refractory giardiasis after an outbreak in Norway. J Infect 2008; 56: 268-273. https://doi.org/10.1016/j.jinf.2008.01.013
  276. Escobedo AA, Almirall P, Chirino E, Pacheco F, Duque A, Avila I. Treatment of refractory paediatric giardiasis using secnidazole plus albendazole: a case series. Infect Med 2018; 26: 379-384. https://infezmed.it/media/journal/Vol_26_4_2018_14.pdf
  277. Arguello-Garcia R, Leitsch D, Skinner-Adams T, Ortega-Pierres MG. Drug resistance in Giardia: mechanisms and alternative treatments for giardiasis. Adv Parasitol 2020; 107: 201-282. https://doi.org/10.1016/bs.apar.2019.11.003
  278. Hutchison JG, Johnston NM, Plevey MV, Thankhiew I. Aidney C. Clinical trial of mebendazole, a broad-spectrum anthelminthic. Br Med J 1975; 2: 309-310. https://doi.org/10.1136/bmj.2.5966.309
  279. Al-Waili NS, Al-Waili BH, Saloom KY. Therapeutic use of mebendazole in giardial infections. Trans R Soc Trop Med Hyg 1988; 82: 438. https://doi.org/10.1016/0035-9203(88)90156-3
  280. Gascon J, Corachan M. Mebendazole in giardial infections: a reply. Trans R Soc Trop Med Hyg 1990; 84: 754. https://doi.org/10.1016/0035-9203(90)90180-M
  281. Al-Waili NS, Hasan NU. Mebendazole in giardial infection: a comparative study with metronidazole. J Infect Dis 1992; 165: 1170-1171. https://doi.org/10.1093/infdis/165.6.1170
  282. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD. Antiprotozoal activities of benzimidazoles and correlations with β-tubulin sequence. Antimicrob Agents Chemother 1994; 38: 2086-2090. https://doi.org/10.1128/AAC.38.9.2086
  283. Goodhew EB, Secor EV. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates. Sex Transm Infect 2013; 89: 479-484. https://doi.org/10.1136/sextrans-2013-051032
  284. Juliano C, Martinotti MG, Cappuccinelli P. "In vitro" effect of microtubule inhibitors on Trichomonas vaginalis. Microbiologica 1985; 8: 31-42. https://europepmc.org/article/med/3871893
  285. Canete R, Escobedo AA, Almirall P, Gonzalez ME, Brito K, Cimerman S. Mebendazole in parasitic infections other than those caused by soil-transmitted helminths. Trans R Soc Trop Med Hyg 2009; 103: 437-442. https:/doi/org/10.1016/j.trstmh.2008.11.029
  286. Pattman RS, Sprott MS, Kearns AM, Earnshaw M. Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports. Genitourin Med 1989; 65: 274-275. http://dx.doi.org/10.1136/sti.65.4.274
  287. McDonald LM, Armson A, Thompson RCA, Reynoldson JA. Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol Biochem parasitol 2004; 138: 89-96. https://doi.org/10.1016/j.molbiopara.2004.08.001
  288. Fayer R, Fetterer R. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. J Parasitol 1995; 81: 794-795. https://doi.org/10.2307/3283980
  289. Weiss LM. Chapter 109. Microsporidiosis. In Ryan ET, Hill DR, Solomon T, Aronson NE, Endy TP eds, Hunter's Tropical Medicine and Emerging Infectious Diseases, 10th ed. Edinburgh, Scotland. Elsevier. 2020, pp 825-831. https://doi.org/10.1016/B978-0-323-55512-8.00109-5
  290. Blanshard C, Ellis DS, Tovey DG, Dowell S, Gazzard BG. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS 1992; 6: 311-313. https://doi.org/10.1097/00002030-199203000-00009
  291. Nacey CJ, Clarke AM, Fraser P, Metcalfe T, Bonsor G, Curry A. Chronic microsporidian infection of the nasal mucosae, sinuses and conjunctivae in HIV disease. Genitourin Med 1992; 68: 179-181. http://doi.org/10.1136/sti.68.3.179
  292. Deplazes P, Mathis A, Baumgartner R, Tanner I, Weber R. Immunologic and molecular characteristics of Encephalitozoon-like microsporidia isolated from humans and rabbits indicate that Encephalitozoon cuniculi is a zoonotic parasite. Clin Infect Dis 1996; 22: 557-559. https://doi.org/10.1093/clinids/22.3.557
  293. Hocevar SN, Paddock CD, Spak CW, Rosenblatt R, Diaz-Luna H, Castillo I, Luna S, Friedman GC, Antony S, Stoddard RA, Tiller RV, Peterson T, Blau DM, Sriam RR, da Silva A, de Almeida M, Benedict T, Goldsmith CS, Zaki SR, Visvesvara GS, Kuehnert MJ. Microsporidiosis acquired through solid organ transplantation: a public health investigation. Ann Intern Med 2014; 160: 213-220. https://doi.org/10.7326/M13-2226
  294. Dore GJ, Marriott DJ, Hing MC, Harkness JL, Field AS. Disseminated microsporidiosis due to Septata intestinalis in nine patients infected with the human immunodeficiency virus: response to therapy with albendazole. Clin Infect Dis 1995; 21: 70-76. https://doi.org/10.1093/clinids/21.1.70
  295. Dacha S, Pham D, Cai Q. Microsporidiosis: an unusual endoscopic finding. Clin Gastroenterol Hepatol 2014; 12: 37-38. https://doi.org/10.1016/j.cgh.2013.08.030
  296. Molina JM, Chastang C, Goguel J, Michiels JF, Sarfati C, Desportes-Livage I, Horton J, Derouin F, Modai J. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998; 177: 1373-1377. https://doi.org/10.1086/515268
  297. Leder K, Ryan N, Spelman D, Crowe SM. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998; 30: 331-338. https://doi.org/10.1080/00365549850160594
  298. Tremoulet AH, Avila-Aguero ML, Paris MM, Canas-Coto A, Ulloa-Gutierrez R, Faingezicht I. Albendazole therapy for Microsporidium diarrhea in immunocompetent Coasta Rican children. Ped Infect Dis J 2004; 23: 915-918. https://doi.org/10.1097/01.inf.0000141724.06556.f9
  299. Molina JM, Sarfati C, Beauvais B, Lemann M, Lesourd A, Ferchal F, Casin I, Lagrange P, Modigliani R, Derouin F, Modal J. Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biological features. J Infect Dis 1993; 167: 217-221. https://doi.org/10.1093/infdis/167.1.217
  300. Dieterich DT, Lew EA, Kotler DP, Poles MA, Orenstein JM. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994; 169: 178-183. https://doi.org/10.1093/infdis/169.1.178
  301. Wichro E, Hoelzi D, Krause R, Bertha G, Reinthaler F, Wenisch C. Microsporidiosis in travel-associated chronic diarrhea in immune-competent patients. Am J Trop Med Hyg 2005; 73: 285-287. https://doi.org/10.4269/ajtmh.2005.73.285
  302. Galvan AL, Sanchez AMM, Perez Valentin MA, Henriques-Gil N, Izquierdo F, Fenoy S, del Aguila C. First cases of microsporidiosis in transplant recipients in Spain and review of the literature. J Clin Microbiol 2011; 49: 1301-1306. https://doi.org/10.1128/JCM.01833-10
  303. Molina JM, Goguel J, Sarfati C, Michiels JF, Desportes-Livage I, Balkan S, Chastang C, Cotte L, Maslo C, Struxiano A, Derouin F, Decazes JM. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. AIDS 2000; 14: 1341-1348. https://doi.org/10.1097/00002030-200007070-00006
  304. Lanternier F, Boutboul D, Menotti J, Chandesris MO, Sarfati C, Mamzer Bruneel MF, Calmus Y, Mechai F, Viard JP, Lecuit M, Bougnoux ME, Lortholary O. Microsporidiosis in solid organ transplant recipient: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis 2009; 11: 83-88. https://doi.org/10.1111/j.1399-3062.2008.00347.x
  305. George B, Coates T, McDonald S, Russ G, Cherian S, Nolan J, Brealey J. Disseminated microsporidiosis with Encephalitozoon species in a renal transplant recipient. Nephrology 2012; 17 (suppl): 5-8. https://doi.org/10.1111/k.1440-1797.2012.01580.x
  306. Boileau M, Ferreira J, Ahman I, Lavallee C, Qvarnstrom Y, Dufresne SF. Successful treatment of disseminated Anncalia algerae microsporidial infection with combination fumagillin and albendazole. Open Forum Infect Dis 2016; 3: 1-4. https://doi.org/10.1093/ofid/ofw158
  307. Katiyar SK, Edlind TD. In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives. Antimicrob Agents Chemother 1997; 41: 2729-2732. https://doi.org/10.1128/AAC.41.12.2729
  308. Morris DL, Smith PG. Albendazole in hydatid disease-hepatocellular toxicity. Trans R Soc Trop Med Hyg 1987; 81: 343-344. https://doi.org/10.1016/0035-9203(87)90259-8
  309. Todorov T, Vutova K, Petkov D, Mechkov G, Kolev K. Albendazole treatment of human cystic echinococcosis. Trans R Soc Trop Med Hyg 1987; 81: 343-344. https://doi.org/10.1016/0035-9203(88)90161-7
  310. Yildiz BO, Haznedaroglu I, Coplu L. Albendazole-induced amegakaryocytic thrombocytopenic purpura. Ann Pharmacol 1998; 32: 842. https://doi.org/10.1345/aph.17433
  311. Polat C, Dervisoglu A, Hokelek M, Yetim I, Buyukkarabacak Y, Ozkutuk Y, Erzurumlu K. Dual treatment of albendazole in hepatic hydatidosis: new therapeutic modality in 52 cases. J Gastroenterol Hepatol 2005; 20: 421-425. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1440-1746.2004.03535.x
  312. Ben Fredj N, Chaabane A, Chadly Z, Ben Fadhel N, Boughattas NA, Aouam K. Albendazole-induced associated acute hepatitis and bicytopenia. Scand J Infect Dis 2014; 46: 149-151. https://doi.org/10.3109/00365548.2013.835068
  313. Pourgholami MH, Szwajcer M, Chin M, Liauw W, Seef J, Galettis P, Morris DL, Links M. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemother Pharmacol 2010; 65: 597-605. https://doi.org/10.1007/s00280-009-1157-8
  314. Kim MK, Park HW, Kim WJ, Park CM, Hong JY, Cho SJ, Jang MK. A case of acute drug-induced hepatotoxicity after albendazole treatment. Korean J Intern Med 2008; 75: 564-568 (in Korean). https://www.ekjm.org/journal/view.php?number=18621
  315. Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW. Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci 2008; 23: 903-905. https://doi.org/10.3346/jkms.2008.23.5.903-5
  316. Marin Zuluaga JI, marin Castro AE, Perez Cadavid JC, Restrepo Guttierez JC. Albendazole-induced granulomatous hepatitis: a case report. J Med Case Rep 2013; 7: 201. https://doi.org/10.1186/1752-1947-7-201
  317. Bilgic Y, Yilmaz C, Cagin YF, Atayan Y, Karadag N, Harputluoglu MMM. Albendazole induced recurrent acute toxic hepatitis: a case report. Acta Gastro-enterol Belg 2017; 80: 309-311. https://www.ageb.be/Articles/Volume%2080%20(2017)/Fasc2/11-Bilgic.pdf
  318. Narciso-Schiavon JL, Delziovo HA, Santos LEB, Shiozawa MBC, Schiavon LL. Recurrent albendazole-induced acute hepatitis. Rev Colomb Gastroenterol 2018; 33: 463-467 (in Spanish). https://doi.org/10.22516/25007440.206
  319. Amoruso C, Fuoti M, Miceli V, Zito E, Celano MR, De Giorgi A, Nebbia G. Acute hepatitis as a side effect of albendazole: a pediatric case. Pediatr Med Chir2009; 31: 176-178 (in Italian). https://europepmc.org/article/med/19839402
  320. Nandi M, Sarkar S. Albendazole-induced recurrent hepatitis. Indian Pediatr 2013; 50: 1064. https://www.indianpediatrics.net/nov2013/1064-1065.pdf https://doi.org/10.1007/s13312-013-0285-8
  321. Shah C, Mahapatra A, Shukla A, Bhatia S. Recurrent acute hepatitis caused by albendazole. Trop Gastroenterol 2013; 34: 38-39. http://dx.doi.org/10.7869/tg.2012.90
  322. Grama A, Aldea CO, Burac L, Delean D, Bulata B, Sirbe C, Duca E, Boghitoiu D, Coroleuca A, Pop TL. Etiology and outcome of acute liver failure in children-The experience of a single tertiary care hospital from Romania. Children 2020; 7: 282. https://doi.org/10.3390/children7120282
  323. Batzlaff CM, Pupaibool J, Sohail MR. Acute renal failure associated with albendazole therapy in a patient with trichinosis. BMJ Case Rep 2014; 2014: bcr2013200668. https://doi.org/10.1136/bcr-2013-200668
  324. Tolomeo M, Colomba C, Meli M, Cascio A. Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome. J Clin Pharm Ther 2019; 44: 985-987. https://doi.org/10.1111/jcpt.13033
  325. Seitz R, Schwerk W, Arnold R. Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis. Z Gastroenterol 1983; 21: 324-329 (in German). https://europepmc.org/article/med/6613213
  326. Bekhti A, Pirotte J. Hepatotoxicity of mebendazole. Relationship with serum concentrations of the drug. Gastroenterol Clin Biol 1987; 11: 701-703. https://europepmc.org/article/med/3692093
  327. Miskovitz PF, Javitt NB. Leukopenia associated with mebendazole therapy of hydatid disease. Am J Trop Med Hyg 1980; 29: 1356-1358. https://doi.org/10.4269/ajtmh.1980.29.1356
  328. Chen KT, Twu SJ, Chang HJ, Lin RS. Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health 2003; 93: 489-492. https://doi.org/10.2105/ajph.93.3.489
  329. Kwa MSG, Veenstra JG, Roos MH. Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in β-tubulin isotype 1. Mol Biochem Parasitol 1994; 63: 299-303. https://doi.org/10.1016/0166-6851(94)90066-3
  330. De Clercq D, Sacko M, Behnke J, Gilbert F, Dorny P, Vercruysse J. Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. Am J Trop Med Hyg 1997; 57: 25-30. https://doi.org/10.4269/ajtmh.1997.57.25
  331. Furtado LVF, Bello ACP, dos Santos HA, Carvalho MRS, Rabelo EML. First identification of the F200Y SNP in the β-tubulin gene linked to benzimidazole resistance in Ancylostoma caninum. Vet Parasitol 2014; 206: 313-316. https://doi.org/10.1016/j.vetpar.2014.10.021
  332. Jaeger LH, Carvalho-Costa FA. Status of benzimidazole resistance in intestinal nematode populations of livestock in Brazil: a systematic review. BMC Vet Res 2017; 13: 358. https://doi.org/10.1186/s12917-017-1282-2
  333. Furtado LFV, de Aguiar PHN, Zuccherato LW, Teixeira TTG, Alves WP, da Silva VJ, Gasser RB, Rabelo EML. Albendazole resistance induced in Ancylostoma ceylanicum is not due to single-nucleotide polymorphisms (SNPs) at codons 167, 198, or 200 of the beta-tubulin gene, indicating another resistance mechanism. Parasitol Res 2019; 118: 837-849. https://doi.org/10.1007/s00436-019-06218-9
  334. Geerts S, Gryseels B. Anthelmintic resistance in human helminths: a review. Trop Med Int Health 2001; 6: 915-921. https://doi.org/10.1046/j.1365-3156.2001.00774.x
  335. Albonico M, Wright V, Bickle Q. Molecular analysis of the β-tubulin gene of human hookworms as a basis for possible benzimidazole resistance on Pemba Island. Mol Biochem Parasitol 2004; 134: 281-284. https://doi.org/10.1016/j.molbiopara.2003.12.008
  336. Bennett A, Guyatt H. Reducing intestinal nematode infections: efficacy of albendazole and mebendazole. Parasitol Today 2000; 16: 71-74. https://doi.org/10.1016/S0169-4758(99)01544-6
  337. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, Taylor M. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 2003; 81: 343-352. https://www.scielosp.org/article/bwho/2003.v81n5/343-352/en/
  338. Flohr C, Tuyen L, Lewis S, Minh TT, Campbell J, Britton J, Williams H, Hien TT, Farrar J, Quinnell RJ. Low efficacy of mebendazole against hookworm in Vietnam: two randomized controlled trials. Am J Trop Med Hyg 2007; 76: 732-736. https://doi.org/10.4269/ajtmh.2007.76.732
  339. Humphries D, Mosites E, Otchere J, Twum WA, Woo L, Jones-Sanpei H, Harrison LM, Bungiro RD, Benham-Pyle B, Bimi L, Edoh D, Bosompem K, Wilson M, Cappello M. Epidemiology of hookworm infection in Kintampo North Municipality, Ghana: patterns of malaria coinfection, anemia, and albendazole treatment failure. Am J Trop Med Hyg 2011; 84: 792-800. https://doi.org/10.4269/ajtmh.2011.11-0003
  340. Diawara A, Drake LJ, Suswillo RR, Kihara J, Bundy DAP, Scott ME, Halpenny C, Stothard JR, Prichard RK. Assays to detect β-tubulin codon 200 polymorphism in Trichuris trichiura and Ascaris lumbricoides. PLoS Negl Trop Dis 2009; 3: e397. https://doi.org/10.1371/journal.pntd.0000397
  341. Diawara A, Halpenny C, Churcher TS, Mwandawiro C, Kihara J, Kaplan RM, Streit TG, Idaghdour Y, Scott ME, Basanez MG, Prichard RK. Association between response to albendazole treatment and β-tubulin frequencies in soil-transmitted helminths. PLoS Negl Trop Dis 2013; 7: e2247. https://doi.org/10.1371/journal.pntd.0002247
  342. Vercruysse J, Behnke JM, Albonico M, Ame SM, Angebault C, Bethony JM, Engels D, Guillard B, Nguyen TV, Kang G, Kattula D, Kotze AC, McCarthy JS, Mekonnen Z, Montresor A, Periago MV, Sumo L, Tchuente LA, Dang TC, Zeynudin A, Levecke B. Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis 2011; 5: e948. https://doi.org/10.1371/journal.pntd.0000948
  343. Schwab AE, Boakye DA, Kyelem D, Prichard RK. Detection of benzimidazole resistance-associated mutations in the filarial nematode Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am J Trop Med Hyg 2005; 73: 234-238. https://doi.org/10.4269/ajtmh.2005.73.234
  344. Upcroft J, Mitchell R, Chen N, Upcroft P. Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in β-tubulin. Microb Drug Resist 1996; 2: 303-308. https://doi.org/10.1089/mdr.1996.2.303
  345. Lacey E, Watson TR. Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay. Biochem Pharmacol 1985; 34: 3603-3605. https://doi.org/10.1016/0006-2952(85)90742-7
  346. Rolin S, Amri HS, Batt AM, Levy M, Bagrel D, Siest G. Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatic cell lines. Cell Biol Toxicol 1989; 5: 1-14. https://doi.org/10.1007/BF00141060
  347. Pourgholami MH, Cai ZY, Lu Y, Wang L, Morris DL. Albendazole; a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006; 12: 1928-1935. https://doi.org/10.1158/1078-0432.CCR-05-1181
  348. Ehteda A, Galettis P, Pillai K, Morris DL. Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice. BMC Cancers 2013; 13: 86. https://doi.org/10.1186/1471-2407-13-86
  349. Javdan S, Nayeri H, Vaseghi G. Cytotoxic effect of albendazole on the breast cancer and melanoma. Zahedan J Res Med Sci 2018; 20: e9100. https://doi.org/10.5812/zjrms.9100
  350. Priotti J, Baglioni V, Garcia A, Rico MJ, Leonardi D, Lamas MC, Marquez MM. Repositioning of anti-parasitic drugs in cyclodextrin inclusion complexes for treatment of triple-negative breast cancer. AAPS PharmEciTech 2018; 19: 3734-3741. https://doi.org/10.1208/s12249-018-1169-y
  351. Patel K, Doudican NA, Schiff PB, Orlow SJ. Albendazole sensitizes cancer cells to ionizing radiation. Radiat Oncol 2011; 6: 160. https://doi.org/10.1186/1748-717X-6-160
  352. Cho YK, Shin EY, Uehara H, Ambati B. Antiangiogenesis effect of albendazole on the cornea. J Ocul Pharmacol Ther 2019; 35: 1-8. https://doi.org/10.1089/jop.2018.0103
  353. Zhang X, Zhao J, Gao X, Pei D, Gao C. Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis. Exp Ther Med 2017; 13: 595-603. https://doi.org/10.3892/etm.2016.3992
  354. Yang MH, Ha IJ, Um JY, Ahn KS. Albendazole exhibits anti-neoplastic actions against gastric cancer cells by affecting STAT3 and SATAT5 activation by pleiotropic mechanism(s). Biomedicines 2021; 9: 362. https://doi.org/10.3390/biomedicines9040362
  355. Ghasemi F, Black M, Vizeacoumar F, Pinto N, Ruicci KM, Le CCSH, Lowerison MR, Leong HS, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Mymryk JS, Boutros PC, Datti A, Barrett JW, Nichols AC. Repurposing albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. Oncotarget 2017; 8: 71512-71519. https://doi.org/10.18632/oncotarget.17292
  356. Zhang QL, Lian DD, Zhu MJ, Li XM, Lee JK, Yoon TJ, Lee JH, Jiang RH, Kim CD. Antitumor effect of albendazole on cutaneous squamous cell carcinoma (SCC) cells. BioMed Res Int 2019; 2019: 3689517. https://doi.org/10.1155/2019/3689517
  357. Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep 2018; 8: 11926. https://doi.org/10.1038/s41598-018-30158-6
  358. Movahedi F, Li L, Gu W, Xu ZP. Nanoformulations of albendazole as effective anticancer and antiparasite agents. Nanomedicine 2017; 12: 2555-2574. https://doi.org/10.2217/nnm-2017-0102
  359. Racoviceanu R, Trandafirescu C, Voicu M, Ghiulai R, Borcan F, Dehelean C, Watz C, Aigner Z, Ambrus R, Coricovac DE, Circioban D, Mioc A, Szuhanek CA, Soica C. Solid polymeric nanoparticles of albendazole: synthesis, physico-chemical characterization and biological activity. Molecules 2020; 25: 5130. https://doi.org/10.3390/molecules25215130
  360. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 2002; 8: 2963-2969.
  361. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Therapeut 2002; 1: 1201-1209. https://mct.aacrjournals.org/content/1/13/1211.full-text.pdf
  362. Martarelli D, Pompei P, Baldi C, Mazzoni G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 2008; 61: 809-817. https://doi.org/10.1007/s00280-007-0538-0
  363. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 2008; 6: 1308-1315. https://doi.org/10.1158/1541-7786.MCR-07-2159
  364. Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology 2011; 13: 974-982. https://doi.org/10.1093/neuonc/nor077
  365. Nygren P, Fraknas M, Agerup B, Larsson R. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J cancer Res Clin Oncol 2013; 139: 2133-2140. https://doi.org/10.1007/s00432-013-1539-5
  366. De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Dimassi SA, Atlas M, Boockvar J, Ruggieri R, Symons M. Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol Med 2017; 23: 50-56. https://doi.org/10.2119/molmed.2017.00011
  367. Lai SR, Castello SA, Robinson AC, Koehler JW. In vitro anti-tubulin effects of mebendazole and fenbendazole in canine glioma cells. Vet Comp Oncol 2017; 15: 1445-1454. https://doi.org/10.1111/vco.12288
  368. Elayapillai S, Ramraj S, Benbrook DM, Bieniasz M, Wang L, Pathuri G, Isingizwe ZR, Kennedy AL, Zhao YD, Lightfoot S, Hunsucker LA, Gunderson CC. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol 2021; 160: 302-311. https://doi.org/10.1016/j.ygyno.2020.10.010
  369. Rushworth LK, Hewit K, Munnings-Tomes S, Somani S, James D, Shanks E, Dufes C, Straube A, Patel R, Leung HY. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. Br J Cancer 2020; 122: 517-527. https://doi.org/10.1038/s41416-019-0681-5
  370. Dobrosotskaya IY, Hammer GD, Schteingart DE, Maturen KE, Worden FP. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocr Pract 2011; 17: e59-e62. https://doi.org/10.4158/EP10390.CR
  371. Nygren P, Larsson R. Drug repositioning from bench to bed-side: tumor remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta Oncol 2014; 53: 427-428. https://doi.org/10.3109/0284186X.2013.844359

피인용 문헌

  1. Failure of Repeated MDA with Albendazole for Trichuriasis Control in Schoolchildren of the Yangon Region, Myanmar vol.59, pp.6, 2021, https://doi.org/10.3347/kjp.2021.59.6.607
  2. Cyclodextrin Dispersion of Mebendazole and Flubendazole Improves In Vitro Antiproliferative Activity vol.9, pp.12, 2021, https://doi.org/10.3390/pr9122185
  3. Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles vol.13, pp.22, 2021, https://doi.org/10.3390/cancers13225650